Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

2.203 -0.107 (-4.65%)
Streaming Delayed Price Updated: 11:33 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
4 Analysts Have This to Say About Gossamer Bio
 
Via Benzinga
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
What 5 Analyst Ratings Have To Say About Gossamer Bio
Analysts have provided the following ratings for Gossamer Bio (NASDAQ:GOSS) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Gossamer Bio
Within the last quarter, Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings: 
Via Benzinga
Where Gossamer Bio Stands With Analysts
Within the last quarter, Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for Gossamer Bio
Gossamer Bio (NASDAQ:GOSS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2022
Upgrades 
Via Benzinga
Gossamer Bio: Q2 Earnings Insights
  Gossamer Bio (NASDAQ:GOSS) reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Where Gossamer Bio Stands With Analysts
Analysts have provided the following ratings for Gossamer Bio (NASDAQ:GOSS) within the last quarter: 
Via Benzinga
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a... 
Via Benzinga
Insider Buying This Major Airline Stock, Here's 3 Stocks Insiders Are Buying
Although US stocks closed higher on Friday, there were a few notable insider trades. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
  
Via Benzinga
Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program
 
Via Benzinga
Why Cannabis Companies Traded Higher; Here's 60 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Dow Sinks Amid Disappointing Data, Bank Earnings
Wall Street worries over potential rate hikes from the Fed following yesterday's inflation reading. 
Via Talk Markets
Analyst Ratings for Gossamer Bio
Over the past 3 months, 5 analysts have published their opinion on Gossamer Bio (NASDAQ:GOSS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday
Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Twitter, Delta Air Lines And 45 Stocks Moving In Wednesday's Mid-Day Session
Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares jumped 122.4% to $6.76. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th. 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Gossamer Bio Announces $120 Million Private Placement Financing
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
71 Biggest Movers From Yesterday
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update
From Gossamer Bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.